Monday, May 25

Walmart's blowout quarter couldn't save its stock

Strong e-commerce growth and record revenues weren't enough to offset a cautious full-year outlook that sent shares lower.

Walmart's guidance is the more honest signal than its blowout quarter

Walmart posted $177.8 billion in Q1 revenue with e-commerce up 26%, but the company's warning of a full-year growth slowdown tied to macroeconomic pressure is what moved the stock.

A retailer of Walmart's scale doesn't guide conservatively by accident, and the gap between a blowout quarter and a cautious outlook is exactly the kind of signal the market reads as a ceiling, not a floor.

Gilead's back-to-back regulatory wins signal a pipeline that is finally delivering

Gilead Sciences secured FDA approval for Hepcludex as the first U.S. treatment for chronic hepatitis D, and separately won a European backing for Trodelvy in triple-negative breast cancer, two meaningful label expansions in a single day.

For a company that has long been defined by its hepatitis C franchise, landing in two new disease areas simultaneously is the kind of diversification that changes how analysts model its long-term revenue ceiling.

The market punished BJ's Wholesale despite a clean beat on every metric

BJ's Wholesale Club reported Q1 revenues up 10%, record membership fee income, and 28% digital comparable sales growth, yet a sharp single-session selloff followed a quarter with no obvious miss.

When a clean beat produces a sharp selloff, the story is almost never about the quarter itself but about what the guidance implies for the growth rate investors had already priced in.

  • Booz Allen beat earnings despite civil-segment revenue weakness
  • ExxonMobil seeks approval for ninth Guyana offshore development

Today's theme was the gap between reported results and forward expectations: Walmart and BJ's both delivered strong numbers and both got sold on what comes next.

Watch Gilead's commercial launch timeline for Hepcludex closely, since the speed of physician adoption in a rare-disease indication will be the first real test of whether today's approval translates into meaningful revenue.

You shouldn't have to go looking. See your first brief today.

Download on the App Store